Alzamend Neuro (NASDAQ: ALZN), a clinical-stage biotech company focused on treatments for Alzheimer’s and other neurological conditions, has announced a strategic collaboration with QMENTA, an AI-powered medical imaging firm, to support upcoming Phase II clinical trials of its lead drug candidate, AL001.
The five studies will be conducted at Massachusetts General Hospital and focus on evaluating how AL001 compares to currently available lithium carbonate treatments, particularly in terms of how effectively the drug delivers lithium to the brain and reduces its presence in the bloodstream. This comparison could offer insights into reducing side effects commonly associated with lithium, such as those affecting kidney and thyroid function.
QMENTA’s role will center around managing and analyzing imaging data from the trials through its cloud-based platform, which integrates artificial intelligence to enhance workflow efficiency and ensure regulatory compliance. The goal is to improve visibility into AL001’s brain-targeted effects and help optimize study design for future trials.
Preclinical studies have already shown promising results—mice treated with AL001 demonstrated better lithium absorption in the brain while maintaining lower blood levels compared to standard lithium salts. If these outcomes translate to humans, AL001 could represent a safer and more convenient alternative to traditional lithium therapies, which often require regular blood monitoring due to a narrow therapeutic window.
The collaboration marks a significant move for Alzamend as it advances clinical development in Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD. The company is betting that its novel formulation, combining lithium, salicylate, and L-proline, could reduce treatment complications and expand the utility of lithium-based therapy.
CEO Stephan Jackman said that QMENTA’s advanced imaging platform offers a vital layer of support for the upcoming trials and could eventually serve as a foundation for broader clinical adoption.
The post Alzamend Neuro Taps AI Imaging Partner QMENTA for Phase II AL001 Trials at Massachusetts General appeared first on PRISM MarketView.
